

IFW Image

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

NAKANO et al.

Serial No. 10/575,253

Filed: April 10, 2006

For: GENOMICALLY MODIFIED CELL NEUTRALIZED TO  
SERUM-FREE SYSTEM



Atty. Ref.: 249-423

Group: unknown

Examiner: Unknown

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

August 22, 2006

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] **N/C**
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] **\$180.00**
3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
**\$180.00**

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- a) The required Statement made in item 8 below; or
- b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- b) The required Statement is stated in item 8 below.
8. Statement under 37 CFR 1.97(e)
- a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information

contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By:



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

249-423

APPLICANT

NAKANO et al.

(Use several sheets if necessary)

FILING DATE

April 10, 2006

SERIAL NO.

10/575,253



GROUP

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2005-0276805A1	12/2005	Hanai et al			
	2006-0024800A1	2/2006	Hanai et al			
	2005-0272916A1	12/2005	Hanai et al			
	2005-0262593A1	11/2005	Kanda et al			
	2006-0063254A1	3/2006	Kanda et al			
	2006-0064781A1	3/2006	Kanda et al			
	2006-0078990A1	4/2006	Kanda et al			
	2006-0078991A1	4/2006	Kanda et al			
	6,946,292	9/2005	Kanda et al			
	SN 11/279,748		Kanda et al			4/2006
	2005-0287138 A1	12/2005	Iida et al			
	SN 09/958,307		Kanda et al			10/2001
	5,728,568	3/1998	Sullivan			
	6054304	4/2000	Taniguchi et al.			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES NO
1	97/27303	7/1997	WO		
2	97/30087	8/1997	WO		
3	97/37683	10/1997	WO		
4	99/54342	10/1999	WO		
5	99/64618	12/1999	WO		
6	00/61739	10/2000	WO		

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

7	Furukawa et al Protein, Nucleic Acid and Enzyme, 43, 2309-2317 (1998)..
8	Maly et al, Cell, vol 86, 643-653, Aug. 23, 1996. .
9	Wright et al. Tibtech, 15, 26-32 (1997). .
10	Breton et al, Glycobiology, 8, No. 1, 87-94 (1998). .
11	Asano et al, The EMBO Journal, vol. 16, No. 8, pp 1850-1857 (1997). .
12	Shitara et al. Journal of Immunological Methods, 167, 271-278 (1994). .
13	Oriol et al. Glycobiology, 9, No. 4, 323-334 (1999). .
14	Raju, et al. (2000) Glycobiology, 10(5): 477-86. .
15	Stryer (1988) Biochemistry, 3rd Ed., Freeman and Co., New York, NY, pp. 35-37.
16	Shinkawa, et al. (2003) J. Biol. Chem., 278(5): 3466-73. .
17	Jones, et al. (2001) Pharmacogenomics J., 1(2): 126-34. .
18	Lifely, et al. (1995) Glycobiology, 5(8): 813-22. .

\*Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)


**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

249-423

APPLICANT

NAKANO et al.



SERIAL NO.

10/575,253

(Use several sheets if necessary)

FILING DATE

GROUP

April 10, 2006

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,453,363	9-1995	Rudolph			
	4,816,567	3-1989	Cabilly			
	5,858,983	01/1999	Seed et al			
	6,602,684	08/20034	Umana et al			
	2004/0072290	04/2004	Umana et al			
	2003/0157108	08/2003	Presta			
	60/337,642	10/2001	Presta			
	60/347,694	01/2002	Presta			
	60/082,581	04/1998	Umana et al			

**FOREIGN PATENT DOCUMENTS**

TRANSLATION

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
19	882794	9/1998	EPO				
20	WO 94/16094	7/1994	WIPO				
21	623352	11/1994	EPO				
22	WO 91/19501	12/1991	WIPO				
38	98/54964	12/1998	WIPO				
24	WO 03/035835	05/2003	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

25	Wilson et al, "Structural analysis of N-glycans from allergenic grass, ragweed and tree pollens: Core 1, 3-linked fucose and xylose present in all pollens examined", Glycoconjugate Journal 15(11):1055-1070 (1998)
27	Boyd et al, Molecular Immunology, 1995, Vol. 32, No. 17/18, pp 1311-1318
28	Clark, Chem. Immunol. 1997, Vol. 65, pp 88-110
30	Ohyama et al, The Journal of Biological Chemistry, 1998, Vol. 273, No. 23, pp 14582-14587
31	Sullivan et al, The Journal of Biological Chemistry, 1998, Vol. 273, No. 14, pp 8193-8202
32	Ripka et al, Archives of Biochemistry and Biophysics, 1986, Vol. 249, No. 2, pp 533-545
33	Ripka et al, Somatic Cell and Molecular Genetics, 1986, Vol. 12, No. 1 pp 51-62
34	Shields et al, The Journal of Biological Chemistry, 2002, Vol. 277, No. 30, pp 26733-26740
35	Jefferies et al (BioChem J. 268 :529-537 (1990)
36	Routier et al (Glycoconjugate Journal 14 :201-207 (1997))
37	Potelligent™ Technology, BioWa, Inc, internet address: biowa.com/news/pdf/Bio2003%20&%20Anti-Cancer%20BioWa%20Non%20Confidential.pdf#search=%22Potelligent%20Technology%20BioWa%2C%20Inc.%20pdf%22, July 21, 2004
41	Yamane-Ohnuki et al, Biotechnology & Bioengineering, vol 87, No. 5, September 5, 2004
40	Rituxan product insert, 2 pages, © 2004 IDEC Pharmaceuticals Corporation and Genentech Inc
39	Nose, J Immunology (1990) vol 145, No. 3, 910-914

\*Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)